Doxazosin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Benign Prostatic Hyperplasia

• Alfuzosin
• Dutasteride
• Finasteride
• Sildenafil
• Tadalafil
• Tamsulosin

Other medications in Urology

• Dutasteride/Tamsulosin
• Fesoterodine
• Mirabegron
• Oxybutynin
• Oxybutynin Topical
• Phenazopyridine
• Phosphodiesterase 5 inhibitors
• Silodosin

What Doxazosin is approved for (FDA label)

Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.

Source: Read the full FDA label on DailyMed. Label effective date: August 14, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Doxazosin (FDA label)

Doxazosin Tablets, USP are available as 2 mg (white to off-white, capsule shaped, scored tablets, imprinted "APO" on one side and "094" with a partial bisect on the other side) Tablets: 2 mg

Source: FDA prescribing information (DailyMed). Set ID: 30a6bb83-f91b-4c4f-a849-4f2be3735a0e. SPL document ID: 5905fa54-02ba-24ec-e063-6294a90aa7a6. Label effective date: August 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Doxazosin (FDA label)

The most commonly reported adverse reactions from clinical trials are Fatigue, malaise, hypotension, and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Benign Prostatic Hyperplasia (BPH) The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients.

Source: FDA prescribing information (DailyMed). Set ID: 30a6bb83-f91b-4c4f-a849-4f2be3735a0e. SPL document ID: 5905fa54-02ba-24ec-e063-6294a90aa7a6. Label effective date: August 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Doxazosin (FDA label)

The use of doxazosin tablets is contraindicated in patients with a hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any of its components. Hypersensitivity to doxazosin, other quinazolines, or any other ingredient in doxazosin tablets. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 30a6bb83-f91b-4c4f-a849-4f2be3735a0e. SPL document ID: 5905fa54-02ba-24ec-e063-6294a90aa7a6. Label effective date: August 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Doxazosin (FDA label)

Postural hypotension with or without syncope may occur. ( 5.1 ) Risk of Intraoperative Floppy Iris Syndrome during cataract surgery. ( 5.2 ) Screen for the presence of prostate cancer prior to treatment for BPH and at regular intervals afterwards. ( 5.3 ) 5.1 Postural Hypotension Postural hypotension with or without symptoms (e.g., dizziness) may develop within a few hours following administration of doxazosin tablets. However, infrequently, symptomatic postural hypotension has also been reported later than a few hours after dosing. As with other alpha-blockers, there is a potential for syncope, especially after the initial dose or after an increase in dosage strength. Advise patient how to avoid symptoms resulting from postural hypotension and what measures to take should they develop.

Source: FDA prescribing information (DailyMed). Set ID: 30a6bb83-f91b-4c4f-a849-4f2be3735a0e. SPL document ID: 5905fa54-02ba-24ec-e063-6294a90aa7a6. Label effective date: August 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Doxazosin (FDA label)

Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. ( 7.1 ) Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. ( 7.2 ) 7.1 CYP 3A Inhibitors In vitro studies suggest that doxazosin is a substrate of CYP 3A4. Strong CYP3A inhibitors may increase exposure to doxazosin. Monitor blood pressure and for symptoms of hypotension when doxazosin tablets are used concomitantly with strong CYP3A inhibitors [ see Clinical Pharmacology ( 12.3 ) ]. 7.2 Phosphodiesterase-5 (PDE-5) Inhibitors Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. Monitor blood pressure and for symptoms of hypotension [ see Warnings and Precautions ( 5.1 ) ].

Source: FDA prescribing information (DailyMed). Set ID: 30a6bb83-f91b-4c4f-a849-4f2be3735a0e. SPL document ID: 5905fa54-02ba-24ec-e063-6294a90aa7a6. Label effective date: August 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.